Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exemestane vs Anastrozole in Advanced Breast Cancer
NCT00128843Phase 2Completed
- Sponsor
- GEICAM
- Start
- Aug 2001
- Primary completion
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of exemestane in breast cancer (2 arms), sponsored by GEICAM. Primary endpoint: Objective Response Rate at 12 months. Started Aug 2001; status: completed.
02
Drugs
exemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00128843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00128843.